← Back to Clinical Trials
Recruiting NCT06083168

NCT06083168 Cardiovascular Disease in Patients With Chronic Kidney Disease: Polish Kidney- Heart Project

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06083168
Status Recruiting
Phase
Sponsor Medical University of Silesia
Condition Chronic Kidney Disease
Study Type OBSERVATIONAL
Enrollment 6,000 participants
Start Date 2023-12-01
Primary Completion 2033-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 6,000 participants in total. It began in 2023-12-01 with a primary completion date of 2033-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an observational longitudinal study which will collect routine demographic, laboratory and clinical parameters of patients with chronic kidney disease (CKD) in the Silesian and Warmia and Mazury Regions (Poland) aimed at predicting incident cardiovascular disease and cardiovascular and renal events using machine learning and artificial intelligence approaches. There will be a subgroup analysis of patients with diabetes and CKD.

Eligibility Criteria

Inclusion Criteria: * CKD defined as estimated glomerular filtration rate (eGFR) \< 60ml/min/1.73 m2 and/or urine albumin creatinine ratio ( UACR) \> 30 mg/g lasting at least 3 months * CKD regardless of eGFR/albuminuria when documented otherwise (by means of imaging, renal biopsy result, genetic background, etc) Exclusion Criteria: * Death during hospital stay * Terminal stage of cancer * Lack of an informed consent

Contact & Investigator

Central Contact

Katarzyna Nabrdalik, assoc. Prof

✉ knabrdalik@sum.edu.pl

📞 0048323704438

Principal Investigator

Katarzyna Nabrdalik, assoc. Prof

PRINCIPAL INVESTIGATOR

Medical University of Silesia

Frequently Asked Questions

Who can join the NCT06083168 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06083168 currently recruiting?

Yes, NCT06083168 is actively recruiting participants. Contact the research team at knabrdalik@sum.edu.pl for enrollment information.

Where is the NCT06083168 trial being conducted?

This trial is being conducted at Olsztyn, Poland, Zabrze, Poland.

Who is sponsoring the NCT06083168 clinical trial?

NCT06083168 is sponsored by Medical University of Silesia. The principal investigator is Katarzyna Nabrdalik, assoc. Prof at Medical University of Silesia. The trial plans to enroll 6,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology